carvedilol has been researched along with Body Weight in 35 studies
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carvedilol attenuated the development and promoted a partial reversal of cachexia in patients with severe chronic heart failure, supporting a role for prolonged sympathetic activation in the genesis of weight loss." | 9.24 | Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial. ( Anker, SD; Clark, AL; Coats, AJS; Katus, HA; Krum, H; Mohacsi, P; Packer, M; Salekin, D; Schultz, MK, 2017) |
| "Chronic heart failure (CHF) is characterized by increased insulin resistance and hyperleptinaemia." | 9.13 | Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. ( Gobec, L; Kovacić, D; Lainscak, M; Marinsek, M; Podbregar, M, 2008) |
| "Data were derived from a prospective, nonplacebo-controlled study of carvedilol for the treatment of paediatric patients with congestive heart failure and analysed using a nonlinear mixed-effects modelling approach (NONMEM, Version V 1." | 9.13 | Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. ( Albers, S; Läer, S; Meibohm, B; Mir, TS, 2008) |
| "In an open clinical study, long-term efficacy and safety of carvedilol were investigated in 154 patients with essential hypertension WHO I-II and diastolic blood pressure (BP) between 95 and 115 mm Hg over a period of 1 year." | 9.06 | Efficacy and safety of carvedilol in the treatment of hypertension. ( Glocke, M; Schnurr, E; Widmann, L, 1987) |
| "We tested the hypothesis that long-term caffeine intake prevents the development of insulin resistance and hypertension in two pathological animal models: the high-fat (HF) and the high-sucrose (HSu) diet rat." | 7.78 | Chronic caffeine intake decreases circulating catecholamines and prevents diet-induced insulin resistance and hypertension in rats. ( Conde, SV; Gonzalez, C; Guarino, MP; Monteiro, EC; Mota Carmo, M; Nunes da Silva, T, 2012) |
| "Treatment with carvedilol reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and NGF-beta to the baseline values." | 5.33 | Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. ( Chang, H; Fang, WJ; Liou, JY; Shyu, KG; Wang, BW, 2005) |
| "Carvedilol attenuated the development and promoted a partial reversal of cachexia in patients with severe chronic heart failure, supporting a role for prolonged sympathetic activation in the genesis of weight loss." | 5.24 | Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial. ( Anker, SD; Clark, AL; Coats, AJS; Katus, HA; Krum, H; Mohacsi, P; Packer, M; Salekin, D; Schultz, MK, 2017) |
| "A prospective 12-week pilot study of carvedilol titrated to 50 mg twice daily was performed among 25 hemodialysis participants with intradialytic hypertension." | 5.16 | Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell dysfunction. ( Inrig, JK; Kim, C; Povsic, TJ; Toto, R; Van Buren, P; Vongpatanasin, W, 2012) |
| "Chronic heart failure (CHF) is characterized by increased insulin resistance and hyperleptinaemia." | 5.13 | Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. ( Gobec, L; Kovacić, D; Lainscak, M; Marinsek, M; Podbregar, M, 2008) |
| "Data were derived from a prospective, nonplacebo-controlled study of carvedilol for the treatment of paediatric patients with congestive heart failure and analysed using a nonlinear mixed-effects modelling approach (NONMEM, Version V 1." | 5.13 | Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. ( Albers, S; Läer, S; Meibohm, B; Mir, TS, 2008) |
| "Metoprolol tartrate was associated with increased weight gain compared to carvedilol; weight gain was most pronounced in subjects with hypertension and diabetes who were not taking insulin therapy." | 5.12 | Body weight changes with beta-blocker use: results from GEMINI. ( Anderson, KM; Bakris, GL; Bangalore, S; Bell, DS; Fonseca, V; Holdbrook, FK; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Wright, JT, 2007) |
| "In an open clinical study, long-term efficacy and safety of carvedilol were investigated in 154 patients with essential hypertension WHO I-II and diastolic blood pressure (BP) between 95 and 115 mm Hg over a period of 1 year." | 5.06 | Efficacy and safety of carvedilol in the treatment of hypertension. ( Glocke, M; Schnurr, E; Widmann, L, 1987) |
| "We tested the hypothesis that long-term caffeine intake prevents the development of insulin resistance and hypertension in two pathological animal models: the high-fat (HF) and the high-sucrose (HSu) diet rat." | 3.78 | Chronic caffeine intake decreases circulating catecholamines and prevents diet-induced insulin resistance and hypertension in rats. ( Conde, SV; Gonzalez, C; Guarino, MP; Monteiro, EC; Mota Carmo, M; Nunes da Silva, T, 2012) |
| "Six months of BB therapy with carvedilol or long-acting metoprolol is associated with differential effects on body weight and hormonal levels in cachectic and noncachectic subjects with CHF." | 3.72 | Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure. ( Androne, AS; Hryniewicz, K; Hudaihed, A; Katz, SD, 2003) |
| "These data indicate that carvedilol provides remarkable cardioprotection, by suppressing severe hypertension-induced cardiac remodeling and myopathies at doses that do not reduce systemic blood pressure." | 3.70 | Carvedilol prevents severe hypertensive cardiomyopathy and remodeling. ( Barone, FC; Campbell, WG; Feuerstein, GZ; Nelson, AH, 1998) |
| "The cardioprotective properties of carvedilol (a vasodilating beta-adrenoceptor blocking agent) were studied in a rat model of dilated cardiomyopathy induced by autoimmune myocarditis." | 3.70 | Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy. ( Aizawa, Y; Fuse, K; Hanawa, H; Hasegawa, G; Higuchi, H; Hirono, S; Ito, M; Kato, K; Kodama, M; Naito, M; Nakazawa, M; Ohta, Y; Tanabe, N; Watanabe, K, 2000) |
| "Carvedilol (BM 14190) is a new potent and well-tolerated beta-adrenoceptor antagonist with vasodilating properties." | 2.66 | Circadian antihypertensive profile of carvedilol (BM 14190). ( Distler, A; Gotzen, R; Meyer-Sabellek, W; Schulte, KL, 1987) |
| "Intradialytic hypertension is a condition where there is an increase in blood pressure (BP) from pre- to post-hemodialysis; this condition has been recently identified as an independent mortality risk factor in hypertensive hemodialysis patients." | 2.53 | Mechanisms and Treatment of Intradialytic Hypertension. ( Inrig, JK; Van Buren, PN, 2016) |
| "Inflammation is one of the main mechanisms of pancreatic β-cell damage and the development of type 1 diabetes (T1D)." | 1.62 | Carvedilol prevents pancreatic β-cell damage and the development of type 1 diabetes in mice by the inhibition of proinflammatory cytokines, NF-κB, COX-2, iNOS and oxidative stress. ( Amirshahrokhi, K; Zohouri, A, 2021) |
| "Treatment with carvedilol restored VMH lactate levels and improved the adrenaline (epinephrine) responses." | 1.51 | Carvedilol prevents counterregulatory failure and impaired hypoglycaemia awareness in non-diabetic recurrently hypoglycaemic rats. ( Chan, O; Farhat, R; Fisher, SJ; Knight, N; Sejling, AS; Su, G, 2019) |
| "Carvedilol has beneficial effects on cardiac function in patients with heart failure but its effect on ovariectomy-induced myocardial contractile dysfunction remains unclear." | 1.39 | Carvedilol prevents ovariectomy-induced myocardial contractile dysfunction in female rat. ( Fernandes, AA; Fiorim, J; Forechi, L; Lima, FL; Pavan, BM; Potratz, FF; Ribeiro, RF; Stefanon, I; Vassallo, DV, 2013) |
| "Losartan treatment could be an effective tool to restore normal vascular reactivity in the renal circulation of the fructose-fed rat." | 1.38 | The effect of losartan and carvedilol on renal haemodynamics and altered metabolism in fructose-fed Sprague-Dawley rats. ( Abdulla, MH; Abdullah, NA; Johns, EJ; Sattar, MA, 2012) |
| "Treatment with carvedilol for 5 weeks prevented the inhibition of endothelium-dependent relaxation and the decrease of serum NO levels caused by diabetes." | 1.34 | Carvedilol ameliorates endothelial dysfunction in streptozotocin-induced diabetic rats. ( Chen, F; Fu, GS; Huang, H; Ke, XY; Qian, LB; Wang, HP; Xia, Q, 2007) |
| "Treatment with carvedilol reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and NGF-beta to the baseline values." | 1.33 | Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. ( Chang, H; Fang, WJ; Liou, JY; Shyu, KG; Wang, BW, 2005) |
| "Carvedilol treatment increased activities of antioxidant enzymes and expression of Bcl-2 in healthy rats as well as diabetic rats." | 1.33 | Carvedilol protected diabetic rat hearts via reducing oxidative stress. ( Huang, H; Pan, XH; Qian, LB; Shan, J; Wang, HP, 2006) |
| "Treatment with carvedilol is associated with a limitation of increased myostatin expression in the failing ventricular myocardium." | 1.33 | Myostatin expression in ventricular myocardium in a rat model of volume-overload heart failure. ( Chang, H; Lu, MJ; Shyu, KG; Sun, HY; Wang, BW, 2006) |
| "Carvedilol treatment significantly blocked adrenoceptors during the treatment period, delayed development (eye opening), reduced growth, and reduced arterial pressure and heart rate." | 1.32 | Pre-weaning carvedilol treatment in spontaneously hypertensive rats. ( Anderson, WP; Boesen, EI; Kett, MM; Lambert, GW, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.71) | 18.7374 |
| 1990's | 4 (11.43) | 18.2507 |
| 2000's | 17 (48.57) | 29.6817 |
| 2010's | 11 (31.43) | 24.3611 |
| 2020's | 1 (2.86) | 2.80 |
| Authors | Studies |
|---|---|
| Amirshahrokhi, K | 1 |
| Zohouri, A | 1 |
| Farhat, R | 1 |
| Su, G | 1 |
| Sejling, AS | 1 |
| Knight, N | 1 |
| Fisher, SJ | 1 |
| Chan, O | 1 |
| Wu, T | 1 |
| Li, H | 1 |
| Lan, Q | 1 |
| Zhao, ZA | 1 |
| Cao, Y | 1 |
| Zhou, P | 1 |
| Wan, S | 1 |
| Zhang, J | 1 |
| Jiang, H | 1 |
| Zhang, Q | 1 |
| Pang, J | 1 |
| Yadav, CH | 1 |
| Najmi, AK | 1 |
| Akhtar, M | 1 |
| Khanam, R | 1 |
| Van Buren, PN | 1 |
| Inrig, JK | 2 |
| Clark, AL | 1 |
| Coats, AJS | 1 |
| Krum, H | 1 |
| Katus, HA | 1 |
| Mohacsi, P | 1 |
| Salekin, D | 1 |
| Schultz, MK | 1 |
| Packer, M | 1 |
| Anker, SD | 1 |
| Li, YC | 1 |
| Ge, LS | 1 |
| Yang, PL | 1 |
| Tang, JF | 1 |
| Lin, JF | 1 |
| Chen, P | 1 |
| Guan, XQ | 1 |
| Conde, SV | 1 |
| Nunes da Silva, T | 1 |
| Gonzalez, C | 1 |
| Mota Carmo, M | 1 |
| Monteiro, EC | 1 |
| Guarino, MP | 1 |
| Abdulla, MH | 1 |
| Sattar, MA | 1 |
| Abdullah, NA | 1 |
| Johns, EJ | 1 |
| Hamdy, N | 1 |
| El-Demerdash, E | 1 |
| Van Buren, P | 1 |
| Kim, C | 1 |
| Vongpatanasin, W | 1 |
| Povsic, TJ | 1 |
| Toto, R | 1 |
| Ribeiro, RF | 1 |
| Potratz, FF | 1 |
| Pavan, BM | 1 |
| Forechi, L | 1 |
| Lima, FL | 1 |
| Fiorim, J | 1 |
| Fernandes, AA | 1 |
| Vassallo, DV | 1 |
| Stefanon, I | 1 |
| Padi, SS | 1 |
| Chopra, K | 1 |
| Santos, DL | 1 |
| Moreno, AJ | 1 |
| Leino, RL | 1 |
| Froberg, MK | 1 |
| Wallace, KB | 1 |
| Podbregar, M | 2 |
| Voga, G | 1 |
| Yuan, Z | 1 |
| Shioji, K | 1 |
| Kihara, Y | 1 |
| Takenaka, H | 1 |
| Onozawa, Y | 1 |
| Kishimoto, C | 1 |
| Watanabe, K | 2 |
| Abe, Y | 1 |
| Sato, S | 1 |
| Wahed, M | 1 |
| Wen, J | 1 |
| Narasimman, G | 1 |
| Ma, M | 1 |
| Ali, F | 1 |
| Saito, Y | 1 |
| Suresh, P | 1 |
| Shirai, K | 1 |
| Soga, M | 1 |
| Nagai, Y | 1 |
| Takahashi, T | 1 |
| Hasegawa, G | 2 |
| Naito, M | 2 |
| Tachikawa, H | 1 |
| Tanabe, N | 2 |
| Kodama, M | 2 |
| Aizawa, Y | 2 |
| Yamaguchi, K | 1 |
| Miyazaki, M | 1 |
| Kakemi, M | 1 |
| Hryniewicz, K | 1 |
| Androne, AS | 1 |
| Hudaihed, A | 1 |
| Katz, SD | 1 |
| Boesen, EI | 1 |
| Lambert, GW | 1 |
| Anderson, WP | 1 |
| Kett, MM | 1 |
| Cabassi, A | 1 |
| Coghi, P | 1 |
| Govoni, P | 1 |
| Barouhiel, E | 1 |
| Speroni, E | 1 |
| Cavazzini, S | 1 |
| Cantoni, AM | 1 |
| Scandroglio, R | 1 |
| Fiaccadori, E | 1 |
| Shyu, KG | 2 |
| Liou, JY | 1 |
| Wang, BW | 2 |
| Fang, WJ | 1 |
| Chang, H | 2 |
| Huang, H | 2 |
| Shan, J | 1 |
| Pan, XH | 1 |
| Wang, HP | 2 |
| Qian, LB | 2 |
| Lu, MJ | 1 |
| Sun, HY | 1 |
| Fu, GS | 1 |
| Chen, F | 1 |
| Ke, XY | 1 |
| Xia, Q | 1 |
| Messerli, FH | 1 |
| Bell, DS | 1 |
| Fonseca, V | 1 |
| Katholi, RE | 1 |
| McGill, JB | 1 |
| Phillips, RA | 1 |
| Raskin, P | 1 |
| Wright, JT | 1 |
| Bangalore, S | 1 |
| Holdbrook, FK | 1 |
| Lukas, MA | 1 |
| Anderson, KM | 1 |
| Bakris, GL | 1 |
| Kovacić, D | 1 |
| Marinsek, M | 1 |
| Gobec, L | 1 |
| Lainscak, M | 1 |
| Albers, S | 1 |
| Meibohm, B | 1 |
| Mir, TS | 1 |
| Läer, S | 1 |
| Nagano, T | 1 |
| O'Harrow, S | 1 |
| Sponer, G | 1 |
| Zimmer, HG | 1 |
| Barone, FC | 2 |
| Nelson, AH | 2 |
| Ohlstein, EH | 1 |
| Willette, RN | 1 |
| Sealey, JE | 1 |
| Laragh, JH | 1 |
| Campbell, WG | 2 |
| Feuerstein, GZ | 2 |
| Shimamura, K | 1 |
| Sekiguchi, F | 1 |
| Matsuda, K | 1 |
| Yamamoto, K | 1 |
| Tanaka, S | 1 |
| Sunano, S | 1 |
| Shibutani, T | 1 |
| Hashimoto, H | 1 |
| Tanaka, M | 1 |
| Intengan, HD | 1 |
| Schiffrin, EL | 1 |
| Ohta, Y | 1 |
| Nakazawa, M | 1 |
| Higuchi, H | 1 |
| Fuse, K | 1 |
| Ito, M | 1 |
| Hirono, S | 1 |
| Hanawa, H | 1 |
| Kato, K | 1 |
| Schnurr, E | 1 |
| Widmann, L | 1 |
| Glocke, M | 1 |
| Meyer-Sabellek, W | 1 |
| Schulte, KL | 1 |
| Distler, A | 1 |
| Gotzen, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Blood Pressure, Endothelial Cell Dysfunction, and Outcomes in Dialysis Patients[NCT00827775] | Phase 4 | 55 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"ALDH bright cells reported as percentage of mononuclear cells. These were assayed using flow cytometry~CD34/CD133 endothelial progenitor cells reported as percentage of mononuclear cells. These were assayed using flow cytometry" (NCT00827775)
Timeframe: 12 weeks
| Intervention | % of mononuclear cells (Median) | |
|---|---|---|
| Baseline ALDH bright | Baseline CD34/CD133 endothelial progenitor cells | |
| Control | 0.052 | 0.059 |
"ALDH bright cells reported as percentage of mononuclear cells. These were assayed using flow cytometry~CD34/CD133 endothelial progenitor cells reported as percentage of mononuclear cells. These were assayed using flow cytometry" (NCT00827775)
Timeframe: 12 weeks
| Intervention | % of mononuclear cells (Median) | |||
|---|---|---|---|---|
| Baseline ALDH bright | Follow up ALDH bright | Baseline CD34/CD133 endothelial progenitor cells | Follow up CD34/CD133 | |
| Intervention | 0.034 | 0.027 | 0.033 | 0.029 |
Measured as percent change in brachial artery diameter from baseline to post shear stress for an individual measurement. Follow up measurements were obtained in intervention subjects 12 weeks later (NCT00827775)
Timeframe: 12 weeks
| Intervention | % dilation from baseline (Mean) |
|---|---|
| Baseline FMD | |
| Control | 1.67 |
Measured as percent change in brachial artery diameter from baseline to post shear stress for an individual measurement. Follow up measurements were obtained in intervention subjects 12 weeks later (NCT00827775)
Timeframe: 12 weeks
| Intervention | % dilation from baseline (Mean) | |
|---|---|---|
| Baseline FMD | Follow Up FMD | |
| Intervention | 1.03 | 1.4 |
1 review available for carvedilol and Body Weight
| Article | Year |
|---|---|
Mechanisms and Treatment of Intradialytic Hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Body Weight; Carbazoles; Carvedilol; Dialysis Solutions; En | 2016 |
8 trials available for carvedilol and Body Weight
| Article | Year |
|---|---|
Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Body Weight; Cachexia; Carbazoles; Carvedilol; | 2017 |
Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell dysfunction.
Topics: AC133 Antigen; Adult; Aged; Aldehyde Dehydrogenase; Antigens, CD; Antigens, CD34; Antihypertensive A | 2012 |
Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure.
Topics: Adipose Tissue; Adrenergic beta-Antagonists; Aged; Basal Metabolism; Bisoprolol; Blood Pressure; Bod | 2002 |
Body weight changes with beta-blocker use: results from GEMINI.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Body Weight; C | 2007 |
Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Blood Glucose; Body Weight; Carbazoles; Carvedilol; C | 2008 |
Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Body Weight; Carbazoles; Carvedilol; Child; Child, | 2008 |
Efficacy and safety of carvedilol in the treatment of hypertension.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Pressure; Body Weight; Carbazoles; Carvedil | 1987 |
Circadian antihypertensive profile of carvedilol (BM 14190).
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Body Weight; Carbazoles; Carvedilol; Circadian R | 1987 |
26 other studies available for carvedilol and Body Weight
| Article | Year |
|---|---|
Carvedilol prevents pancreatic β-cell damage and the development of type 1 diabetes in mice by the inhibition of proinflammatory cytokines, NF-κB, COX-2, iNOS and oxidative stress.
Topics: Animals; Blood Glucose; Body Weight; Carvedilol; Cyclooxygenase 2; Cytokines; Diabetes Mellitus, Typ | 2021 |
Carvedilol prevents counterregulatory failure and impaired hypoglycaemia awareness in non-diabetic recurrently hypoglycaemic rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Blood Glucose; Body Weight; Carvedilol; Catheteriza | 2019 |
Protective effects of S-carvedilol on doxorubicin-induced damages to human umbilical vein endothelial cells and rats.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Apoptosis; Body Weight; Carvedilol; Catalase; Ce | 2019 |
Cardioprotective role of H₃R agonist imetit on isoproterenol-induced hemodynamic changes and oxidative stress in rats.
Topics: Adrenergic beta-Agonists; Animals; Antioxidants; Biomarkers; Blood Pressure; Body Height; Body Weigh | 2015 |
Carvedilol treatment ameliorates acute coxsackievirus B3-induced myocarditis associated with oxidative stress reduction.
Topics: Adrenergic Antagonists; Aldehydes; Animals; Body Weight; Carbazoles; Carvedilol; Electrocardiography | 2010 |
Chronic caffeine intake decreases circulating catecholamines and prevents diet-induced insulin resistance and hypertension in rats.
Topics: Adiposity; Adrenergic Antagonists; Animals; Body Weight; Caffeine; Carbazoles; Carvedilol; Catechola | 2012 |
The effect of losartan and carvedilol on renal haemodynamics and altered metabolism in fructose-fed Sprague-Dawley rats.
Topics: Angiotensin II; Animals; Body Weight; Carbazoles; Carvedilol; Fructose; Glucose Tolerance Test; Hemo | 2012 |
New therapeutic aspect for carvedilol: antifibrotic effects of carvedilol in chronic carbon tetrachloride-induced liver damage.
Topics: Acute-Phase Proteins; Adrenergic beta-Antagonists; Alanine Transaminase; alpha-Macroglobulins; Anima | 2012 |
Carvedilol prevents ovariectomy-induced myocardial contractile dysfunction in female rat.
Topics: Adrenergic beta-Antagonists; Animals; Body Weight; Calcium; Carbazoles; Carvedilol; Female; Heart; H | 2013 |
Salvage of cyclosporine A-induced oxidative stress and renal dysfunction by carvedilol.
Topics: Animals; Antioxidants; Blood Pressure; Body Weight; Carbazoles; Carvedilol; Cyclosporine; Disease Mo | 2002 |
Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Algorithms; Animals; Antibiotics, Antineoplastic; Biological Transport; | 2002 |
Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property.
Topics: Acute Disease; Adrenergic beta-Antagonists; Animals; Anti-Inflammatory Agents; Antioxidants; Autoimm | 2004 |
Contribution of sympathetic nervous system activity during administration of carvedilol in rats with dilated cardiomyopathy.
Topics: Animals; Blood Pressure; Body Weight; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dose-Response | 2003 |
Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Biomarkers; Blood Pressure; Body Weight; Cachexia; Carbazoles; Carvedil | 2003 |
Pre-weaning carvedilol treatment in spontaneously hypertensive rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Animals, Suckling; Blood Pressur | 2004 |
Sympathetic modulation by carvedilol and losartan reduces angiotensin II-mediated lipolysis in subcutaneous and visceral fat.
Topics: Adipocytes; Adipose Tissue; Angiotensin II; Animals; Blood Pressure; Body Weight; Carbazoles; Carved | 2005 |
Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart.
Topics: Acetylcysteine; Animals; Antihypertensive Agents; Aorta; Arteries; Blotting, Western; Body Weight; C | 2005 |
Carvedilol protected diabetic rat hearts via reducing oxidative stress.
Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Carbazoles; Carvedilol; Diabetes Mellitus, Experi | 2006 |
Myostatin expression in ventricular myocardium in a rat model of volume-overload heart failure.
Topics: Animals; Antihypertensive Agents; Aorta; Blood Pressure; Body Weight; Carbazoles; Carvedilol; Heart; | 2006 |
Carvedilol ameliorates endothelial dysfunction in streptozotocin-induced diabetic rats.
Topics: Adrenergic beta-Antagonists; Animals; Aorta, Thoracic; Blood Glucose; Blood Pressure; Blotting, West | 2007 |
Norepinephrine-induced changes in rat heart function, metabolism, and weight are antagonized by carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Body Weight; Carbazoles; Carvedilol; Female; Glucosephosphate | 1993 |
Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats.
Topics: Adrenergic beta-Antagonists; Aldosterone; Animals; Antihypertensive Agents; Blood Pressure; Body Wei | 1996 |
Membrane potential of mesenteric artery from carvedilol-treated spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Carbazoles; Carvedilol; Endothelium, | 1998 |
Carvedilol prevents severe hypertensive cardiomyopathy and remodeling.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Blood Pressure; Body Weight; Carbazoles; | 1998 |
Disparate effects of carvedilol versus metoprolol treatment of stroke-prone spontaneously hypertensive rats on endothelial function of resistance arteries.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Carbazoles; Carvedilol; Endothelium, | 2000 |
Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy.
Topics: Animals; Body Weight; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Disease Progression; Endomyoc | 2000 |